The correct way to take rasagiline (Anzilai) and daily precautions

Rasagiline (trade name: Azilect®) is a selective monoamine oxidase-B (MAO-B) inhibitor, mainly used for early monotherapy or levodopa combination therapy in Parkinson's disease (PD). By inhibiting MAO-B, rasagiline can reduce the breakdown of dopamine in the brain and increase dopamine concentrations, thereby improving the motor symptoms of Parkinson's disease, including tremor, myotonia, and bradykinesia. Its highly selective effect also reduces the impact on the metabolism of epinephrine and norepinephrine, and the side effects are relatively mild.

Rasagiline is an oral tablet. It is generally recommended to take 1 mg once daily. It can be taken alone or simultaneously with levodopa. It is recommended to take it at a fixed time, such as in the morning, and avoid changing the taking time at will to keep the blood concentration stable. The tablets should be swallowed whole, with a small amount of water, and should not be broken or chewed to avoid affecting the efficacy of the medicine. For patients with hepatic insufficiency, the need for dose adjustment should be evaluated under the guidance of a physician.

Patients should pay attention to the following points while taking rasagiline:
Avoid high-Tyramine foods: Although rasagiline is highly selective, it is still recommended to limit consumption of excess cheese, yeast extract, or pickled foods to reduce the risk of elevated blood pressure;
Monitor drug interactions: If hypertension or serotonin syndrome may occur when combined with tricyclic antidepressants, clonidine, dextroamphetamine and other drugs, the doctor should be informed of all drugs being used;
Observe adverse reactions: Common side effects include headache, insomnia, mild dizziness and digestive discomfort. If serious abnormal reactions occur, you should seek medical treatment in time.
Patients taking rasagiline for a long time should maintain a regular schedule, moderate exercise and a healthy diet to enhance the therapeutic effect and improve the quality of life. For patients treated with combined levodopa, the dose can be adjusted under the guidance of a physician to reduce movement fluctuations. In addition, regular follow-up is important, including assessment of motor symptoms, non-motor symptoms, and drug tolerance, to ensure that treatment is safe and effective. Generally speaking, standardized use of rasagiline combined with lifestyle management can effectively control the symptoms of Parkinson's disease, delay the progression of the disease, and improve patients' daily living abilities.
Reference link: https://www.drugs.com